Prevention and Treatment of Venous Thromboembolic Events: Focus on Dabigatran Etexilate

This article reviews the pharmacology and clinical evidence of the use of dabigatran etexilate (DE) in the prevention and treatment of venous thromboembolism (VTE). Published data in English language were identified from MEDLINE and Current Content database (1966 to January 30, 2011) using the searc...

Full description

Saved in:
Bibliographic Details
Published in:Clinical Medicine Insights: Therapeutics 2011-01, Vol.2011 (3), p.205-220
Main Author: Cheng, Judy W.M.
Format: Article
Language:English
Subjects:
Care and treatment
Complications and side effects
Development and progression
Prevention
Pulmonary embolism
Risk factors
Thrombosis
Warfarin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This article reviews the pharmacology and clinical evidence of the use of dabigatran etexilate (DE) in the prevention and treatment of venous thromboembolism (VTE). Published data in English language were identified from MEDLINE and Current Content database (1966 to January 30, 2011) using the search terms dabigatran, VTE, deep vein thrombosis, and pulmonary embolism. Citations from available articles were reviewed for additional references. DE is an oral direct thrombin inhibitor that has a rapid onset of action, achieving peak anticoagulation effect in 0.5–2 hours. In clinical studies, DE has demonstrated superiority and non-inferiority to enoxaparin for VTE prophylaxis and non-inferiority to warfarin for VTE treatment. A common side effect of DE is gastrointestinal complaints. The overall rates of major bleeding were low, and minor bleeding was commonly noted but similar in incidence to other anticoagulant (enoxaparin and warfarin). Future studies should focus on long-term efficacy and safety compared to other anticoagulants, and for other clinical indications.
ISSN:1179-559X
1179-559X
DOI:10.4137/CMT.S1176